Cipla

1,511.20
-12.85
(-0.84%)
Market Cap
1,22,046.63 Cr
EPS
51.05
PE Ratio
24.67
Dividend Yield
0.85 %
Industry
Healthcare
52 Week High
1,702.05
52 Week Low
1,317.25
PB Ratio
4.34
Debt to Equity
0.03
Add Ratio

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from32 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy+59.38 %
+59.38 %
Hold+25.00 %
+25.00 %
Sell+15.63 %
+15.63 %

Company News

View All News
Caret
positive
Cipla Receives Weight Upgrade in FTSE All World Index4 days ago
Cipla, a pharmaceutical company, has received a weight upgrade in the FTSE All World Index. This upgrade is expected to result in an inflow of approximately $30.4 million or 2.6 billion rupees into the stock.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,764.75 4,23,422.64 36.32 49,887.20 12.06 9,648 13.77 61.58
5,840.65 1,55,050.91 75.90 8,184.00 0.89 1,600 64.53 55.23
1,511.20 1,22,046.63 24.67 26,520.70 14.17 4,155 47.38 60.28
3,245.05 1,09,827.24 59.25 10,785.70 11.59 1,656 13.54 61.68
2,398.05 98,935.61 47.95 10,615.60 19.57 1,942 -16.38 56.07
1,177.90 98,285.26 18.80 28,905.40 12.36 5,578 1.69 51.86
2,068.75 94,375.87 33.76 20,141.50 19.94 1,936 38.82 54.50
907.35 91,300.64 20.56 19,831.50 13.82 3,831 29.92 48.54
1,194.95 69,402.89 19.93 29,559.20 17.55 3,169 -10.04 61.05
31,101.85 66,089.26 49.48 6,097.20 10.80 1,201 16.01 61.04
Growth Rate
Revenue Growth
14.17 %
Net Income Growth
46.55 %
Cash Flow Change
27.68 %
ROE
29.60 %
ROCE
23.78 %
EBITDA Margin (Avg.)
12.03 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
3,042
3,812
3,410
3,137
3,312
3,581
3,699
3,717
3,510
3,584
4,102
3,887
3,536
4,016
4,081
3,985
4,366
3,973
4,365
4,307
4,395
4,342
5,026
5,241
4,645
5,536
5,547
5,534
5,288
5,421
5,882
5,845
5,801
6,406
6,766
6,690
6,332
6,785
7,152
7,183
Expenses
2,585
2,784
2,669
2,688
3,138
3,039
3,070
2,970
3,076
2,879
3,278
3,095
3,219
3,213
3,310
3,300
3,443
3,084
3,486
3,613
3,743
3,297
3,862
3,938
3,810
4,283
4,294
4,248
4,568
4,232
4,526
4,403
4,748
4,835
4,944
5,051
4,847
4,978
5,165
5,084
EBITDA
457
1,028
741
450
174
543
629
748
434
705
824
792
317
803
771
685
923
889
879
694
652
1,045
1,164
1,303
835
1,253
1,253
1,286
720
1,190
1,356
1,442
1,053
1,571
1,821
1,639
1,484
1,807
1,986
2,099
Operating Profit %
13 %
26 %
21 %
12 %
4 %
15 %
16 %
17 %
12 %
16 %
18 %
19 %
8 %
16 %
16 %
16 %
19 %
21 %
18 %
15 %
13 %
23 %
22 %
24 %
17 %
22 %
22 %
22 %
13 %
20 %
21 %
23 %
16 %
23 %
25 %
22 %
20 %
25 %
26 %
27 %
Depreciation
136
149
158
177
270
204
229
258
632
213
302
522
285
241
282
293
510
268
283
278
346
269
265
248
285
261
253
248
290
254
299
272
346
239
290
233
288
247
272
280
Interest
43
64
64
31
48
32
35
59
33
28
42
9
35
35
44
44
45
52
46
46
53
46
39
48
28
30
38
21
18
18
26
32
34
16
26
30
18
18
15
15
Profit Before Tax
390
892
595
322
-82
401
444
514
-137
557
574
340
199
620
509
449
501
663
681
506
328
799
926
1,022
544
996
996
1,054
448
975
1,100
1,218
745
1,375
1,594
1,474
1,259
1,611
1,789
1,916
Tax
106
242
43
54
5
57
74
129
-74
132
139
-63
46
175
142
127
144
216
207
167
89
233
266
270
132
286
287
297
77
268
303
410
224
377
439
405
327
436
484
342
Net Profit
284
650
552
269
-87
344
370
385
-63
425
435
404
153
446
367
322
358
447
475
339
239
566
659
752
412
710
709
757
371
706
797
808
522
998
1,155
1,068
932
1,176
1,305
1,575
EPS in ₹
3.24
8.09
6.76
3.24
-1.16
4.22
4.41
4.66
-0.77
5.08
5.25
4.98
2.22
5.60
4.68
4.12
4.56
5.93
5.85
4.35
3.05
7.17
8.25
9.28
5.13
8.86
8.82
9.03
4.49
8.51
9.78
9.92
6.51
12.34
14.01
13.08
11.63
14.58
16.13
19.45

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
15,718
21,128
21,037
22,861
23,963
23,663
25,152
27,101
29,463
32,718
Fixed Assets
6,830
9,369
9,492
9,950
9,608
9,683
9,516
9,683
9,161
9,607
Current Assets
7,591
8,841
8,736
10,814
12,427
11,706
13,210
14,711
16,805
19,392
Capital Work in Progress
581
2,061
1,683
981
676
825
969
766
1,093
1,153
Investments
390
758
973
1,259
2,554
1,471
2,710
2,551
3,662
5,449
Other Assets
7,917
8,940
8,889
10,670
11,125
11,684
11,957
14,101
15,547
16,509
Total Liabilities
15,718
21,128
21,037
22,861
23,963
23,663
25,152
27,101
29,463
32,718
Current Liabilities
3,881
7,776
3,374
3,832
3,772
4,393
4,591
4,913
5,110
5,246
Non Current Liabilities
854
1,486
4,682
4,447
4,848
3,212
1,975
1,071
640
670
Total Equity
10,982
11,866
12,982
14,582
15,344
16,057
18,586
21,117
23,714
26,802
Reserve & Surplus
10,629
11,356
12,383
14,068
14,851
15,602
18,165
20,680
23,246
26,545
Share Capital
161
161
161
161
161
161
161
161
161
162

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
389
312
-248
243
-345
234
141
-132
-97
-49
Investing Activities
-950
-4,533
-1,304
-834
-1,688
114
-2,374
-1,858
-2,376
-2,983
Operating Activities
1,173
1,741
2,382
1,463
1,691
3,068
3,755
3,326
3,238
4,134
Financing Activities
165
3,104
-1,326
-386
-349
-2,949
-1,240
-1,600
-958
-1,200

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
36.73 %
36.72 %
36.12 %
36.11 %
33.63 %
33.61 %
33.61 %
33.61 %
33.55 %
33.47 %
33.47 %
33.47 %
33.47 %
30.91 %
30.92 %
29.19 %
FIIs
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.00 %
0.00 %
0.00 %
25.74 %
25.73 %
25.83 %
27.81 %
28.80 %
26.65 %
DIIs
16.79 %
15.91 %
17.41 %
17.61 %
17.72 %
17.12 %
19.71 %
21.13 %
22.10 %
24.34 %
24.18 %
24.33 %
24.42 %
24.95 %
24.16 %
27.71 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.24 %
16.14 %
16.01 %
15.97 %
15.55 %
15.41 %
14.83 %
14.72 %
14.85 %
14.66 %
14.45 %
14.34 %
14.20 %
14.24 %
14.16 %
14.29 %
Others
30.23 %
31.22 %
30.47 %
30.30 %
33.10 %
33.86 %
31.84 %
30.53 %
29.50 %
27.53 %
2.16 %
2.12 %
2.08 %
2.09 %
1.95 %
2.15 %
No of Share Holders
3,64,796
4,08,401
4,10,831
4,51,365
4,18,584
4,18,910
3,88,864
4,04,182
4,75,293
4,66,513
4,26,861
4,25,731
4,36,154
4,63,569
4,70,234
5,25,114

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 2 3 3 4 5 5 8.5 13 0.00
Dividend Yield (%) 0.00 0.37 0.57 0.71 0.49 0.49 0.56 0.57 0.85 0.00

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
6 days ago
USFDA Inspection At Analytical Testing Facility Of Sitec In Mahape Navi Mumbai India
Feb 20, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 20, 2025
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Feb 18, 2025
Announcement under Regulation 30 (LODR)-Investor Presentation
Feb 18, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Feb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 10, 2025
Update On USFDA Inspection At CompanyS Manufacturing Facility In Virgonagar Bengaluru India
Feb 08, 2025
Announcement under Regulation 30 (LODR)-Acquisition
Feb 03, 2025
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Jan 31, 2025
Announcement under Regulation 30 (LODR)-Newspaper Publication
Jan 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Jan 28, 2025
Integrated Filing (Financial)
Jan 28, 2025
Announcement under Regulation 30 (LODR)-Change in Management
Jan 28, 2025
Board Meeting Outcome for Outcome Of Board Meeting Dated 28Th January 2025
Jan 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 28, 2025
Announcement under Regulation 30 (LODR)-Investor Presentation
Jan 28, 2025
Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended 31St December 2024.
Jan 28, 2025
Announcement under Regulation 30 (LODR)-Change in Management
Jan 23, 2025
USFDA Inspection At Manufacturing Facility Of Medispray In Kundaim Goa India
Jan 20, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Jan 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Jan 15, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Jan 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Jan 08, 2025
Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Tuesday 28Th January 2025
Jan 06, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Dec 05, 2024
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Dec 02, 2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Dec 02, 2024
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Nov 30, 2024
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Nov 28, 2024
Disclosure Under Regulation 30(5) Of The SEBI (LODR) Regulations, 2015
Nov 18, 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Nov 15, 2024
USFDA Inspection At Company''s Manufacturing Facility In Virgonagar, Bengaluru, India
Nov 13, 2024
Announcement under Regulation 30 (LODR)-Change in Directorate
Nov 12, 2024
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Nov 02, 2024
Update On USFDA Inspection At Company''s Manufacturing Facility In Goa, India
Oct 30, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Oct 29, 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
Oct 29, 2024
Board Meeting Outcome for Outcome Of Board Meeting Dated 29Th October 2024
Oct 29, 2024
Announcement under Regulation 30 (LODR)-Investor Presentation
Oct 29, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Oct 29, 2024
Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30Th September 2024
Oct 29, 2024
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Oct 25, 2024
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations, 2015')
Oct 17, 2024
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Oct 14, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Oct 11, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Oct 09, 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Oct 05, 2024
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 (''Listing Regulations'')
Oct 01, 2024
Announcement under Regulation 30 (LODR)-Acquisition
Sep 25, 2024

Technical Indicators

RSI(14)
Neutral
64.76
ATR(14)
Volatile
27.67
STOCH(9,6)
Overbought
90.92
STOCH RSI(14)
Overbought
100.00
MACD(12,26)
Bullish
8.24
ADX(14)
Weak Trend
16.96
UO(9)
Bearish
65.33
ROC(12)
Uptrend But Slowing Down
4.26
WillR(14)
Overbought
-7.72

About Cipla

Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS therapeutic areas. Cipla has a global presence with manufacturing facilities and operations in India and international markets, including the United States, South Africa, and other countries. The company focuses on developing and producing generic and branded generic medicines, as well as expanding into consumer healthcare, biosimilars, and specialty business through its New ventures segment.
Chairperson NameY K Hamied